Announcements Trials
Browse Landscape

Phase

Phase 2 21Phase 1 4Phase NA 2Phase 3 2Phase 1/2 2Phase 4 1

Status

Completed 18Recruiting 10Active not recruiting 10Terminated 5Unknown 4Withdrawn 2Not yet recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1Advanced Non-small Cell Lung Cancer 1

Interventions

Cyclophosphamide 51fludarabine 38Injections 32Gemcitabine 25Paclitaxel 24Cisplatin 22Radiotherapy 19toripalimab 18pembrolizumab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 14Nivolumab 14Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Immunotherapy, Adoptive 11Cetuximab 11Bevacizumab 10Irinotecan 9Drug Therapy 9sintilimab 8Etoposide 8aldesleukin 7Taxes 7Rituximab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Unknown × osimertinib × Clear all
NCT05489731 2023-06-15

VIC-1911

Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd.

Phase 1 Unknown
72 enrolled
Thoracic

Advanced Non-small Cell Lung Cancer

NCT04448379 2020-12-28

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Shanghai JMT-Bio Inc.

Phase 1 Unknown
48 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03891615 2020-12-16

Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer

Massachusetts General Hospital

Phase 1 Unknown
30 enrolled
Thoracic

Lung Neoplasms

NCT03050411 2017-02-10

Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer

Peking University Third Hospital

Phase 1 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡